Juvenile Systemic Sclerosis
- Author: Donald A Person, MD, FAAP, FACR; Chief Editor: Harumi Jyonouchi, MD more...
Juvenile systemic sclerosis (JSSc) is a rare connective tissue disease of unknown etiology. Characteristic features include fibrosis of the skin, subcutaneous tissues, and internal organs as well as abnormalities of the vascular and immune systems occurring in children 16 and younger. This disease is one of the most severe rheumatologic conditions diagnosed in children.
One of the earliest processes thought to occur in JSSc is vascular injury. This results in upregulation of endothelial cell adhesion molecules, which facilitates local platelet aggregation and infiltration of inflammatory cells. This endothelial injury is manifested clinically as Raynaud phenomenon, pulmonary hypertension, and renovascular hypertension.
These inflammatory cells release cytokines, including transforming growth factor beta (TGF-β) and interleukin-1 (IL-1). Among its many effects, IL-1 is known to stimulate the release of platelet-derived growth factor, which stimulates fibroblasts to increase production and deposition of extracellular matrix components such as collagen, fibronectin, and glycosaminoglycans. This fibrosis may affect any organ of the body, most commonly the skin, GI tract, lungs, heart, kidneys, and musculoskeletal system.
Little is known about the role of the various autoantibodies, such as ANA, seen in almost all cases of juvenile systemic sclerosis, but their presence is suggestive of an autoimmune process underlying the aforementioned vascular injury and fibrosis. Resistance of lymphocytes to apoptosis seen in these patients is a potential mechanism for the persistence of autoreactive T cells in juvenile systemic sclerosis.
JSSc is a rare childhood disorder, an orphan disease whose incidence is said to be approximately 0.05 per 100,000 children. In addition, 5-10% of adult cases of systemic sclerosis arise before age 16 years, thus meeting the age criterion for JSSc. New criteria aimed at more uniformly defining JSSc will hopefully aid in better estimation of incidence and prevalence of the condition.
Mortality rates in JSSc are reportedly lower than in adult systemic sclerosis. Five and 20-year survival rates for JSSc are 89% and 69%, respectively.
The greatest morbidity and mortality is seen in those children who develop pulmonary, cardiac, and renal manifestations of the disease. A recently published report reveals that the most significant predictors of mortality at the time of diagnosis are pericarditis, elevated creatinine levels, and fibrosis on chest radiography. The most common cause of early death in patients with juvenile systemic sclerosis is heart failure due to dilated cardiomyopathy, likely related to pulmonary hypertension and myocardial fibrosis.
In a review of 153 patients, those who died had a significantly shorter time to diagnosis from onset of symptoms compared with patients that were still alive at follow-up 8.8 vs 23 months. This demonstrates that those patients who eventually die due to complications of JSSc likely have a more aggressive form that is more quickly recognized due to the severity of symptoms. This is consistent with mortality rates of most studies that show most deaths from JSSc occur within the first 5 years after diagnosis.
Morbidity from the disease is seen in most patients in the form of fibrosis of the skin, which may lead to contractures and loss of mobility, and Raynaud phenomenon with associated pain and paresthesias, as well as digital ulcers. Arthralgias, arthritis, and muscle weakness may occur in as many as a quarter of patients, and a small number may experience dyspnea, weight loss and dysphagia as well.
In the United States, adult systemic sclerosis is more common in blacks than in whites, with a ratio of 2:1. No specific demographic data are available for JSSc.
Females are affected more often than males, with an overall female-to-male ratio of approximately 3.6:1, much lower than the 15:1 female-to-male predominance seen in adults.
A child must be younger than 17 years at the time of disease onset to the meet the criteria for JSSc. The youngest patient documented with JSSc was only a few months old at disease onset. The average age of onset is 8.1-8.8 years in the two largest published case series. Due to the rarity of this condition and the subtle nature by which it can first appear, the average time from symptom onset to diagnosis is 1.9 years, taking as long as 12 years in some cases. Of note, children who died in these studies were diagnosed almost 2 years later than the average child with juvenile systemic sclerosis.
Johnson SR, Swiston JR, Granton JT. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol. 2008 Aug. 35(8):1584-90. [Medline].
Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006 Dec. 54(12):3971-8. [Medline].
[Guideline] Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May. 68(5):620-8. [Medline].
Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009 Feb. 48(2):119-22. [Medline].
Black CM, Denton CP. Therapy of Systemic Sclerosis. Van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM, eds. Therapy of Systemic Rheumatic Disorders. 1998. 495-545.
Bottoni CR, Reinker KA, Gardner RD, Person DA. Scleroderma in childhood: a 35-year history of cases and review of the literature. J Pediatr Orthop. 2000 Jul-Aug. 20(4):442-9. [Medline].
Foeldvari I. New developments in juvenile systemic and localized scleroderma. Rheum Dis Clin North Am. 2013 Nov. 39(4):905-20. [Medline].
Foeldvari I, Tyndall A, Zulian F, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012 Oct. 51(10):1832-7. [Medline].
Foti R, Leonardi R, Rondinone R, Di Gangi M, Leonetti C, Canova M, et al. Scleroderma-like disorders. Autoimmun Rev. 2008 Feb. 7(4):331-9. [Medline].
Gerhold K, Becker MO. Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications. Clin Exp Rheumatol. 2014 Jun 6. [Medline].
Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J. 2002 Mar. 19(3):571-6. [Medline].
Kaal SE, van Den Hoogen FH, de Jong EM, Viëtor HE. Systemic sclerosis: new insights in autoimmunity. Proc Soc Exp Biol Med. 1999 Oct. 222(1):1-8. [Medline].
LeRoy EC. Pathogenesis of Systemic Sclerosis (scleroderma). Koopman WJ, ed. Arthritis and Allied Conditions. 1997. 1481-90.
Levy BD. Eicosanoids in scleroderma: lung disease hangs in the balance. Arthritis Rheum. 2005 Dec. 52(12):3693-7. [Medline].
Nagaya N. Drug therapy of primary pulmonary hypertension. Am J Cardiovasc Drugs. 2004. 4(2):75-85. [Medline].
Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000 Feb. 43(2):444-51. [Medline].
Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol. 2011 Oct 11. 7(11):676-80. [Medline].
Reiff A, Weinberg KI, Triche T, et al. T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol. 2013 Oct. 149(1):146-55. [Medline].
Rosenkranz ME, Agle LM, Efthimiou P, Lehman TJ. Systemic and localized scleroderma in children: current and future treatment options. Paediatr Drugs. 2006. 8(2):85-97. [Medline].
Russo RA, Katsicas MM. Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol Online J. 2007 May 1. 5:6. [Medline]. [Full Text].
Shimizu M, Hashida Y, Ueno K, et al. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis. Pediatr Cardiol. 2011 Oct. 32(7):1040-2. [Medline].
Silver RM. Variant forms of scleroderma. Koopman WJ, ed. Arthritis and Allied Conditions. 1997. 1465-80.
Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum. 2005 Dec. 52(12):3698-700. [Medline].
Vancheeswaran R, Black CM, David J, Hasson N, Harper J, Atherton D, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum. 1996 Jun. 39(6):1041-9. [Medline].
Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am. 2008 Feb. 34(1):239-55; ix. [Medline].
Zulian F, Martini G. Childhood systemic sclerosis. Curr Opin Rheumatol. 2007 Nov. 19(6):592-7. [Medline].
[Guideline] Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007 Mar 15. 57(2):203-12. [Medline].